ArticleBritish journal of cancer2026

A first-in-human, open-label multicentre Phase 1 study of the orally administered E7386 in patients with selected advanced neoplasms.

T R Jeffry Evans et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.